Economic evaluation of anti-epileptic medicines for autistic children with epilepsy

Tinelli, Michela ORCID: 0000-0002-8816-4389, Roddy, Áine, Knapp, Martin ORCID: 0000-0003-1427-0215, Arango, Celso, Mendez, Maria Andreina, Henderson, Catherine ORCID: 0000-0003-4340-4702, Murphy, Declan, Canitano, Roberto, Oakley, Bethany and Quoidbach, Vinciane (2023) Economic evaluation of anti-epileptic medicines for autistic children with epilepsy. Journal of Autism and Developmental Disorders. ISSN 1573-3432

Text (Tinelli_economic-evaluation-of-anti-epileptic-medicines--published) - Published Version Available under License Creative Commons Attribution. Download (1MB)

• Author
• Author
• Author

Abstract

We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children’s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.

Item Type:	Article
Official URL:	https://www.springer.com/journal/10803
Additional Information:	© 2023 The Authors
Divisions:	Care Policy and Evaluation Centre Health Policy
Subjects:	R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine R Medicine > RM Therapeutics. Pharmacology
Date Deposited:	20 Feb 2023 10:18
Last Modified:	18 Nov 2024 17:03
URI:	http://eprints.lse.ac.uk/id/eprint/118204

Actions (login required)

View Item